Presentation on theme: "APRE Agenzia per la promozione della Ricerca Europea"— Presentation transcript:
1APRE Agenzia per la promozione della Ricerca Europea Caterina Buonocore,Health National Contact Point for Italy,“Part of this presentation is taken from the official material produced by EC, DG Research, Unit F”.
2AGENDA PRESENTAZIONE APRE SETTIMO PROGRAMMA QUADRO (7PQ) Structure and scope of Health themeBasic principlesHealth 2013 Work programme key features / prioritiesHow to find partnersIdentification of opportunities for health researchers under other FP7 themes: KBBE, ICT, NMP, SSH, ENV…Other funding opportunities for health researchersInformation sources
3L' APRE è un Ente di ricerca non profit con obiettivo, sancito dall’articolo 3 del suo statuto, di promuovere la partecipazione italiana ai programmi di ricerca e sviluppo finanziati dalla Commissione Europea.Prima realtà del suo genere in Italia, APRE nasce nel 1989 come “Task Force” del Ministero dell’Università e della Ricerca.Nel 1990 viene poi costituita formalmente da Confindustria, ENEA, FAST e MondimpresaÈ sostenuta da numerose Università e organizzazioni private e pubbliche del mondo accademico, dell’industria e della finanza.[COS’É APRE?]
4Migliorare la “Qualità” della partecipazione italiana nei programmi europei di ricerca su sviluppo e innovazione.Per conto del Ministero dell'Università e della Ricerca (MIUR), APRE ha lo scopo di fornire informazioni, supporto e assistenza sulle modalità di partecipazione ai programmi europei di ricerca e sviluppo tecnologico, ad enti pubblici, enti privati e persone fisiche.Ospita la rete dei National Contact Point (NCP).AssistenzaFormazioneInformazione[MISSION]
5[INTERLOCUTORI] Soci APRE Un po’ di numeri: 110 Soci di cui: 6 associazioni di categoria34 enti di ricerca tra pubblici e privati4 realtà appartenenti al mondo della finanza5 organismi del sistema camerale4 parchi scientifici6 enti della pubblica amministrazione51 universitàAPREAssociazioniindustialiCamere di CommercioParchi ScientificiUniversitàCentri di ricercaIndustrieEnti pubbliciFinanzaSoci APRE[INTERLOCUTORI]
6[RISORSE APRE – SPORTELLI LOCALI] Per rafforzare il sistema della cooperazione tra istituzioni pubbliche e private attive nel settore della ricerca scientifica e tecnologica e promuovere e diffondere la ricerca europea a livello nazionale, APRE dispone di una rete di Sportelli regionali.Gli Sportelli, oltre a fornire tutti i servizi specifici dell'APRE, costituiscono anche una sede per favorire le iniziative promosse dai Soci APRE presenti nella regione, supportando inoltre quelle portate avanti da parte di altre istituzioni ed organizzazioni impegnate nel campo della ricerca e dell'innovazione tecnologicaOspitati e gestiti dai Soci APRE, gli Sportelli APRE sono punti di accesso alle informazioni ad operatività regionale e coordinati dalla sede centrale a Roma.[RISORSE APRE – SPORTELLI LOCALI]
7partecipazione ad eventi e giornate informative APRE BRUSSEL offre ai soci:partecipazione ad eventi e giornate informativediffusione di informazioni aggiornate sulle politiche, iniziative ed opportunità sulla ricerca in Europacollegamento diretto con vari attori della ricerca Europea (Istituzioni Europee, liaison office e organismi di ricerca degli Stati Membri, Confederazioni e Consorzi paneuropei)accompagnamento agli incontri con i funzionari della Commissione Europeala sala riunione per meeting internazionali dei progetti Europei di ricerca[RISORSE APRE – SPORTELLO EUROPA]
8Rappresentanza Italiana Commissione EuropeaRappresentanza ItalianaDelegati Nazionali PQMIURAPRE(NCP)1In qualità di ente ospitante dei NCP, punti di contatto nazionale per il PQ, lavoriamo a servizio della CE che ci forma, coordinati dal MIUR, con i delegati del PQ tra le altre cose, per le attività di raccolta dei contributi scientifici dalla comnunità scientifica trasmessi poi alla Rappresentanza Ita.[MISSION]
9IN ITALIA: COMITATO DI PROGRAMMA SALUTE PUNTI DI CONTATTO NAZIONALI Caterina BuonocoreAPRESilvio Garattini (Mario Negri)Stefano Vella(ISS)Caterina Buonocore(APRE)Bruno MourenzaAPREAlfredo Cesario(IRCSS)
10[MISSION] Proposta vincente APRE ospita i Punti di contatto nazionale del VII Programma Quadro in Italia. Questi sono nominati dal Ministero dell'Università e della Ricerca (MUR) e riconosciuti dalla Commissione Europea.InformazioneConferenzeNews AlertSito web (PubblicazioniAssistenzaInformazioneFormazioneEssere un buon coordinatorePreparazione della propostaCome disseminare i risultati della ricercaProprietà intellettuale e Consortium AgreementFormazioneSupporto prima dell’inizio del progetto (telefono, mail e incontri)Identificazione del tema e del topic FP7Verificare l’elegibilità della propostaPre-screening della propostaAiuto nell‘utilizzo dell’EPSS SystemProposta vincenteSupporto dopo l’inizio del progetto (telefono, mail e incontri)NegoziazioneManagement del progettoDisseminazione dei risultatiReporting[MISSION]
11COME SCEGLIERE IL BANDO GIUSTO IN UN PANORAMA ARTICOLATO SALUTE NEL 7 PQCOME SCEGLIERE IL BANDO GIUSTO IN UN PANORAMA ARTICOLATO
13The 7th Framework programme (FP7) Structure and scope of Health themeBasic principlesHealth 2013 Work programme key features / prioritiesIdentification of opportunities for health researchers under other FP7 themes: KBBE, ICT, NMP, SSH…Other funding opportunities for health researchersInformation sources
14EU research policy Why ? How ? to improve quality of life and to improve competiveness of Europe through collaborationHow ?by pooling resources (funds for Framework Programme)by coordinating national research programmes
15Associazioni di pazienti UniversitàCentri di ricercaPMIInterlocutoriOspedaliIndustriaRicerca clinicaIRCCSAssociazioni di pazienti[INTERLOCUTORI SALUTE]
18EUROPEAN COMMISSION - Research DG 7th FrameworkProgrammeforResearchIndicative breakdown (€ million)EUROPEAN COMMISSION - Research DG
19Collaborative research in the Health theme Main policy drivers:Improving health of European citizensIncreasing competitiveness of European health-related industries and businessesAddressing global health issues, including emerging epidemicsBudget:€6.1 billion over 7 years ( )
20Collaborative research across borders and other barriersbetween countries:at least 3 partners from the 27 EU Member States: Austria, Belgium, Bulgaria, Czech Rep., Cyprus, Denmark, Estonia, Finland, France, Germany, Greece, Hungary, Ireland, Italy, Latvia, Lithuania, Luxembourg, Malta, Netherlands, Poland, Portugal, Rumania, Slovakia, Slovenia, Spain, Sweden, the United Kingdom.or the 12 Associated Countries: Albania, Bosnia-Herzegovina, Croatia, FYROM, Iceland, Israel, Liechtenstein, Montenegro, Norway, Serbia, Switzerland, Turkey.In addition, researchers from anywhere in the world can participate: eg: Australia, Brazil, Canada, China, Egypt, India, Japan, Korea, Russia, South-Africa, USA, … and in many cases, can be funded.
21Collaborative research across borders and other barriersbetween countries but also:between different types of organizations Public & private sector: universities, research centres, large companies, small and medium-sized enterprises (SMEs), etc.between disciplines: multidisciplinary, translational R&D
23The Health Theme Three main activities (“pillars”) Activity 1:Biotechnology,generic tools & technologiesfor healthActivity 2:Translatingresearch for human healthActivity 3:Optimisingthe deliveryof health careThe Innovative Medicines Initiativecross-cutting issues: international cooperation, SMEs, child health, ageing populations, gender-related health issuesActivity 4: Support actions & response to policy needs
24EC Funding Strategy Translational research Clinical capacity Discovery Research GrantsProduct development, PPPDiscoveryPreclinicalPhase I/IIaPhase II + IIIRegulatoryLarge Collaborative ProjectsEDCTPTranslationalresearchClinicalcapacityBottlenecks = Innovative Medicine Initiative (IMI)
25Industry (esp. SME) participation & International Cooperation Policy aspectsIndustry (esp. SME) participation & International CooperationEmphasis and special measures for:Small & Medium-sized Enterprises (SMEs)Opportunities and support measuresInternational Cooperationthe possibility to tackle issues on a global scalean opportunity to extend your networks beyond Europe
27Submission & evaluation Basic principles:Annual calls for proposals (2-stage)Evaluation by panels of independent experts overseen by Independent Observers3 criteria:Science & Technology excellenceImplementation & ManagementPotential ImpactFeedback: Evaluation Summary Reports (ESRs)Experts wanted !Aim: to fund the best R&D proposals
31Priorities for Health in 2012-2013 2013 thematic priorities:Brain researchAnti-microbial resistanceComparative effectiveness (CER)Cross-cutting priorities:Translation of results into applicationsInnovation & SMEsSocial innovationSocial innovation refers to new strategies, concepts, ideas and organizations that meet social needs of all kinds - from working conditions and education to community development and health - and that extend and strengthen civil society.International cooperation
32HEALTHFP7-HEALTH-2013-INNOVATION-1 as main call with an indicative budget of EUR 680 million with broader topics of which many are tailored for SME participation (bottom-up with a minimum percentage of EU funding requested going to SMEs)FP7-HEALTH-2013-INNOVATION-2 as a specific call to boost SME participation for innovative solutions in the health sector with an indicative budget of EUR 140 million. This call has very specific conditions. Maximum project duration is limited to 3 years.2 STAGE EVALUATION. Max 6 pagine:1.1 Concept and objectives1.2 Progress beyond the state-of-the-art1.3 S/T methodology and associated work plan2.1 Expected impacts
337th CALL HEALTH Call identifier: FP7-HEALTH-2013-INNOVATION-1 35 topicsProposal submission and evaluation: two-stage procedure.Date of publication: 10 July 2012Deadline for stage 1 proposals: 02 October 2012 at 17:00:00 (Brussels local time)Indicative budget: EUR 680 million from the 2013 budgetCall identifier: FP7-HEALTH-2013-INNOVATION-22 topicsProposal submission and evaluation: two-stage procedure.Date of publication: 10 July 2012Deadline for stage 1 proposals: 25 September 2012 at 17:00:00 (Brussels local time)Indicative budget: EUR 140 million from the 2013 budget
342013 WP preparation Milestones and meetings Roadmap discussed at PC meeting: 5 September 2011Draft WP v1 (“Orientation paper”) => sent to PC by mid-OctoberMeeting with Advisory Group (9 Nov 2011)PC meeting (9-10 Nov 2011) to discuss draft WP v1PC meeting (14 Feb. 2012) to discuss draft WP v2 => final input by 24 FebruaryInternal draft must be ready by 12 March.Inter-service Consultation (April-May 2012) - draft WP v3Formal PC consultation (June 2012) - draft WP v4Work Programme adoption & publication: 10 July 2012
35Health theme Cross cutting topic relevant to the entire Health theme 0-1 - Boosting the translation of FP projects' results into innovative applications for health. FP7-Health-2013-INNOVATION-2build on the results of projects funded under Health theme of FP6 & FP7.focus on specifications, testing and validation of resultsapplicants must control the IPR to be used in their applicationNew: SMEs must be from Member States or Associated Countries (conditions specified, further changes to come based on INNOV-2 call)Funding scheme: CP-FP, max. €6m/project. MS & AC SMEs only. SME-topic: min. 50% EC contribution to SMEsIndicative budget: €75 million
36The Health theme1: Biotechnology, generic tools and medical for technologies for human health1.1 High-throughput research (closed)1.2 Detection, diagnosis and monitoring1.3 Suitability, safety and efficacy of therapies1.4 Innovative therapeutic approaches and interventions
38Activity 1 Biotech, tools & technologies 1.2 – Detection, Diagnosis & MonitoringDevelopment of imaging technologies for therapeutic interventions in rare diseases.Funding scheme: CP-FP, max. €6m/project. SME-topic: min. 30% EC contribution to SMEs
39Area 1.3 Suitability, Safety and Efficacy of Medicines 39
40Activity 1 Biotech, tools & technologies 1.3 – Suitability, safety & efficacy of medicinesModelling toxic responses in case studies for predictive human safety assessment.Funding scheme: CP-FP, max. €12m/project. Industry topic: min. 15% EC contribution to industry, incl. SMEsOnly one proposal may be selectedInnovative approaches to address adverse immune reactions to biomedical devices, implants & transplant tissues.Funding scheme: CP-FP, max. €6m/project. Industry topic: min. 30% EC contribution to industry, incl. SMEs
41Activity 1 Biotech, tools & technologies 1.3 – Suitability, safety & efficacy of medicinesSafety and efficacy of therapeutic vaccines.Funding scheme: CP-FP, max. €6m/project. Industry topic: min. 30% EC contribution to industry, incl. SMEsDevelopment of alternative in vitro, analytical, immunochemical, and other test methods for quality control of vaccines.Funding scheme: CP-FP, max. €6m/project. New: max. 3 years SME topic: min. 30% EC contribution to SMEs
42Area 1.4 Innovative therapeutic approaches and interventions 42
43Activity 1 Biotech, tools & technologies Controlling differentiation and proliferation in human stem cells intended for therapeutic use.Funding scheme: CP-FP, max. €6m/project. SME topic: min. 15% EC contribution to SMEs
44The Health theme 2: Translating research for human health 2.1 Integrating biological data and processes: large-scale data gathering, systems biology2.2 Research on the brain and related diseases, human development and ageing2.3 Translational research in major infectious diseases: to confront major threats to public health2.4 Translational research in other major diseases
46Activity 2 - Translating research for human health 2.1.1 – Large-scale data gatheringFunctional validation in animal and cellular models of genetic determinants of diseases and ageing processes.Funding scheme: CP-IP, max. €12m/project. SME topic: min. 30% EC contribution to SMEsHigh impact research initiative on metagenomics for personalised medicine approaches.Funding scheme: IP, max. €30m/project; max. 1 project Industry topic: min. 30% EC contribution to industry, incl. SMEsOnly one proposal may be selected
47Research on the brain and brain related diseases Area 2.2.1Research on the brain and brain related diseases47
48Activity 2 - Translating research for human health Prospective longitudinal data collection and Comparative Effectiveness Research (CER) for traumatic brain injury (TBI)Funding scheme: CP-IP, max. €30m/project, one or more projectsDevelopment of effective imaging tools for diagnosis, monitoring and management of mental disordersFunding scheme: CP-FP, max. €6m/project Industry topic: min. 30% EC contribution to industry, incl. SMEs
49Activity 2 - Translating research for human health 2.2.1 – The brain and brain disordersPaediatric conduct disorders characterised by aggressive traits and/or social impairment: from preclinical research to treatmentFunding scheme: CP-FP, max. €6m/project SME topic: min. 15% EC contribution to SMEsPatho-physiology and therapy of epilepsy and epileptiform disordersFunding scheme: CP-IP, max. €12m/project SME topic: min. 15% EC contribution to SMEs– Understanding and combating pain (NEW)Funding scheme: CP-FP, max. €6m/project
502.3.1 – Antimicrobial drug resistance Area 2.3Translational research in major infectious diseases; to confront major threats to public health2.3.0 – Cross cutting issues2.3.1 – Antimicrobial drug resistance2.3.2 – HIV/AIDS, malaria, tuberculosis (closed)2.3.3 – Potentially new & re-emerging epidemics2.3.4 – Neglected infectious diseases50
51Activity 2 - Translating research for human health 2.3.0 – Cross-cutting priorities– Innovation in vaccinesFunding scheme: CP-FP, max. €6m/project. SME topic: min. 30% EC contribution to SMEs
52Activity 2 - Translating research for human health 2.3.1 – Anti-microbial drug resistance– INNOVATION 2 Drugs and vaccines for infections that have developed or are at risk of developing significant antimicrobial resistance.New: SMEs must be from Member States or Associated CountriesFunding scheme: CP-FP, max. €6m/project. MS & AC SMEs only. SME topic: min. 50% EC contribution to SMEsStratified approaches to antibacterial and/or antifungal treatmentFunding scheme: CP-FP, max. €6m/project.
53Activity 2 - Translating research for human health 2.3.3 – Potentially new and re-emerging epidemics– Clinical management of patients in severe epidemics.Funding scheme: IP, max. €24m/project; max. 1 project
54Activity 2 - Translating research for human health 2.3.4 – Neglected infectious diseases– Neglected infectious diseases of Central and Eastern Europe.Funding scheme: FP, max. €3m/project.– Drug development for neglected parasitic diseases.Funding scheme: FP, max. €6m/project.SME topic: min. 15% EC contribution to SMEs
552.4.1 – Cancer Area 2.4 Translational research in other major diseases 2.4.2 – CVD2.4.3 – Diabetes/obesity (closed)2.4.4 – Rare diseases (closed)2.4.5 – Chronic diseases (closed)55
56Activity 2 - Translating research for human health 2.4.1 – Cancer– Investigator-driven treatment trials to combat or prevent metastases in patients with solid cancer.Funding scheme: CP-FP, max. €6m/project.– Strengthening the cancer patient's immune system.Funding scheme: CP-FP, max. €6m/project.Industry topic: min. 30% EC contribution to industry, incl. SMEsInvestigator-driven supportive and palliative care clinical trials and observational studies.Funding scheme: CP-FP, max. €6m/project.
57Activity 2 - Translating research for human health 2.4.2 – Cardiovascular diseases– Discovery research to reveal novel targets for cardiovascular disease treatment.Funding scheme: CP-FP, max. €6m/project.SME topic: min. 30% EC contribution to SMEs– Comparative effectiveness research of existing technologies for prevention, diagnosis and treatment of cardiovascular diseases.Funding scheme: CP-FP, max. €6m/project.: Optimising lifestyle interactions in the prevention and treatment of cardiovascular disease across the lifespan.Funding scheme: CP-FP, Small €3m/project.
58The Health Theme3: Optimising the delivery of healthcare to European citizens3.1 Translating clinical research into clinical practice3.2 Quality, efficiency and solidarity of healthcare systems (closed)3.3 Health promotion and prevention3.4 International public health & health systems (closed)
59Activity 3 Optimising the delivery of healthcare 3.1 – Translating clinical research into clinical practiceComparative Effectiveness Research (CER) in health systems and health services interventions.Funding scheme: CP-FP, max. €6m/project.3.3 – Health promotion and preventionSocial innovation for health promotionFunding scheme: CP-FP, max. €6m/project. SME topic: min. 15% EC contribution to SMEs
60The Health theme 4: Actions across the Theme 4.1 Coordination & Support Actions across the theme4.2 Responding to EU policy needs
61Activity 4 Actions across the theme 4.1 – CSAs across the theme4.1-1 –Supporting industrial participation in EU-funded research in the Health sector.Funding scheme: CA, max. €2m/project, up to one project4.1-2 – Interactions between EU legislation and health research and/or innovation and the effects of its application and implementation on health research and/or innovation.Funding scheme: SA, max. €0.5m/project, one or more projects
62Activity 4 Actions across the theme 4.1 – CSAs across the themeSupport for Presidency events. Organisation of supporting actions and events associated to the Presidency of the European Union"…specifically from mid-2013 to 2015 Presidencies, …"Funding scheme: SA, max. €0.1m/project, one or more projectsPreparing the future for health research and innovation.Funding scheme: SA, max. €0.5m/project, one or more projects 4.1-5: Global initiative on gene-environment interactions in diabetes/obesity in specific populations.Funding scheme: CA, max. €2m/project, up to one project 4.1-6: Mapping chronic non-communicable diseases research activitiesFunding scheme: CA, max. €1m/project, up to one project
63Activity 4 Actions across the theme 4.2 – Responding to EU policy needsInvestigator-driven clinical trials for off-patent medicines using innovative, age-appropriate formulations and/or delivery systems.Funding scheme: CP-FP, max. €6m/project.Industry topic: min. 30% EC contribution to industry, incl. SMEs.Adverse drug reaction research.Funding scheme: CP-FP, max. €3m/project.SME topic: min. 15 % EC contribution to SMEs.New methodologies for clinical trials for small population groups.Funding scheme: CP-FP, max. €3m/project.
64All proposals must address these questions. Ethics: overview (1)Two main questions asked on ethics: The necessity to use i.e. personal data, animals, human tissue in order to achieve the scientific objectives set forth in the proposal. Is there an alternative ? Benefit/burden balance of the research project. What will be the impact of this research, not only regarding scientific advance, but also in terms of human dignity as well as social and cultural impact ?All proposals must address these questions.
65Ethics: overview (2)Applicants must first identify key ethical issues raised by their proposals and explain how they will address them.The main issues are:Informed ConsentResearch on Human embryos/foetusesData Protection and PrivacyResearch on Animals (the ‘3Rs’: Reduce, Replace, Refine)Research involving Developing CountriesDual use (research that could have military applications)3 areas are excluded from funding:- Human reproductive cloning- Intentional germ line modification (except research relating to cancer of the gonads which can be funded)- Creation of human embryos for research or stem cell procurement (including by means of somatic cell nuclear transfer)
665. Identification of opportunities for health researchers under other FP7 themes: KBBE, ICT, NMP, SSH…
68Other funding opportunities for health research within the Cooperation Specific Programme
69Other funding opportunities for health research within the KBBE themeCall identifier: FP7-KBBEProposal submission and evaluation: one-stage procedure.Date of publication: 10 July 2012Deadline for stage 1 proposals: 5 February 2013 at 17:00 (Brussels local time)Indicative budget: EUR 680 million from the 2013 budget–Call 7(WP2013)• Research and Innovation for the benefit of society, with a challenges driven approach to maximize the impact of research funded by the EU• 4 main challenges: the main pillars of bio-economySustainable1) Agriculture and Forestry2) Safe and Sustainable Food and Health Diets3) Unlocking the potential of Aquatic Living Resources4) Sustainable and Competitive Bio-based Industries• Broader topics in terms of budget and research developed, leaving greater freedom to the research community
70Area – ConsumersImpact of food and nutritional behaviour, lifestyle and the socio-economic environment on depression and proposed remedial actions (LCP, Up to one project )Area NutritionNew technologies to study brain function in relation to eating behaviours and mental well-being (LCP, Up to one project )Factors influencing the human gut microbiome and its effect on the development of diet related diseases and brain development (LCP, Up to one project )
71KBBE topicsKBBE : Impact of food and nutritional behaviour, lifestyle and the socioeconomic environment on depression and proposed remedial actions (Max 1 CP-IP. Max EC contribution: 6 M€)KBBE : New technologies to study brain function in relation to eating Behaviour (Max 1 CP-IP. Max EC contribution: 9 M€)KBBE : Factors influencing the human gut microbiome and its effect on the development of diet-related diseases and brain development (Max 1 CP-IP. Max EC contribution: 9 M€)KBBE : Food-based solutions for eradication of vitamin D deficiency and health promotion throughout the life cycle (Max 1 CP-IP. Max EC contribution: 6 M€)
72Other funding opportunities for health research within the ICT themeBUDGET € MillionAPERTURA DEADLINEFP7-ICT10 Luglio 201215 Gennaio 2013 (734M€ from budget 2013)FP7-ICT18 Settembre 201216 Aprile 2013 (242M€ from budget 2013)FP NMP-ICT-FoF4 Dicembre 2012 (70M€ from budget 2013)FP NMP-ENV-ENERGY-ICT-EeB4 December 2012 (40M€ from budget 2013)FP ICT-GCFP7-ICT-2013-SME-DCA15 Gennaio 2013 (20M€ from budget 2013)FP7-ICT-2013-FET-F23 Ottobre 2012 (100M€ from budget 2013)FP7-ICT-2013-C12 Marzo 2013 (50M€ from budget 2013)FP7-ICT-2013-X12 Settembre 201229 Gennaio 2013 (15M€ from budget 2013)FP7-ICT2013-EU-Japan2 Ottobre 201229 Novembre 2012 (9M€ from budget 2013)FP7-ICT2013-EU-Brasil24 Ottobre 2012 (4M€ from budget 2013)WP2013 will support the European Innovation Partnerships on Active and Healthy Ageing (EIP AHA) on Personalized health, active ageing, and independent livingICTs have a catalytic impact in three key areas:Productivity and innovation, by facilitating creativity and managementModernisation of public services, such as health, education and transport.Advances in science and technology, by supporting cooperation and access to information.
73Challenge 5: ICT for Health, Ageing Well, Inclusion and Governance: Personalized health, active ageing, and independent livingPersonalized Guidance Services for lifestyle management and disease prevention.Personalized Guidance Services for management of co-morbidities and integrated care.Personalized Services for Independent Living and Active Ageing.Coordination and Support Actions.Virtual Physiological Human Clinical proof of concept of patient specific computer based modelsPersonal Health Forecasting.Coordination and Support Action to develop an RTD roadmap preparing the ground for in-silico clinical trialsICT for smart and personalised inclusionAccessible and intuitive solutions for personalised interfaces to smart environments and innovative services.
74Other funding opportunities for health research within the NMP themeWork Programme 2013 PrioritiesPPPs (Green Cars, Factories of the Future Energy Efficient Buildings): ~ 36%Cross cutting innovation : ~12%Application-specific innovation : ~26%Raw Materials: ~3%Energy : ~5%Environment/Sustainability: ~9%Health and safety: ~9%NMP Nanotherapeutics to treat bacterial infectious diseasesNMP Biomaterials for Advanced Therapies and Medical Devices in the neurological/neuromuscular or cardiovascular fieldsNMP Biomaterials: Imaging and rapid precise prototyping technology for custom made scaffolds – coordinated call with China
75Other funding opportunities for health research within the ENV themeCall identifier: FP7-ENV-2013-two stageProposal submission and evaluation: two-stage procedure.Date of publication: 10 July 2012Deadline for stage 1 proposals: 16 October 2012 at 17:00:00 (Brussels local time)Indicative budget: EUR million from the 2013 budgetCHALLENGE 6.4 PROTECTING CITIZENS FROM ENVIRONMENTAL HAZARDSENV Assessing individual exposure to environmental stressors and predicting health outcomes: paving the way for an EU-wide assessment (CP, Up to one project )ENV Closing gaps of knowledge and reducing exposure to electromagnetic fields (EMF) (CP, Up to one project )
76Other funding opportunities for health research within the SSH themeCall identifier: FP7-SSHProposal submission and evaluation: one-stage procedure.Date of publication: 12 July 2012Deadline for stage 1 proposals: 31 January 2013 at Brussels local timeIndicative budget: EURDraft Work Programme 2013:SSH The impact of ageing societies on public finances in Europe Health care,SSH Early childhood education and care and the cost of inequitiesSSH The impact of the third sector on socio-economic development in Europe
77Other funding opportunities for health research within the SPACE themeCall identifier: FP7-SPACEProposal submission and evaluation: one-stage procedure.Date of publication: 12 July 2012Deadline: 21 November 2012, at , Brussels local timeIndicative budget: EUR 126 millionResearch and development on next generation products and service lines derived from space-borne data in conjunction with in-situ data is to be targetedActivities could target applications on areas like:Health services, or monitoring conditions for vector borne diseases(…)Earth-analogue research preparing for space exploration
786. Other EU funding opportunities for Health researchers
91Advice for submission & evaluation (1) BasicsEligibility issues - funding scheme, number of partners (esp. for SICA), funding limits, deadlinesScope of proposal with respects to topic (Relevance) “The topic, the whole topic and nothing but the topic ” also pay attention to introduction in work programme and any specific requirements for industry or international participationSize and composition of the consortium - beyond the minimum rules, there are no constraints: bring together the competences needed to do the job.No bonus points for “political correctness” or large consortia
92Advice for submission & evaluation (2) BasicsAddress all 3 criteria – be explicit to evaluatorsAddress the Ethics issues Clear requirements for information on ethics issues* - you must explain what the issues are in the proposal - and how will you manage themFailing to do so can delay negotiation or even exclude a proposal.Respect basic rules and guidelines - font size (legibility) and page number limitations (excess pages will not be considered in the evaluation)*Guide for Applicants, Annex 4, section 4.
93Key factors for success in applying for FP7 funding Competition is tough : only the best projects get fundedthe proposal must address the topic and the work programme (not wishful thinking)the consortium of partners must be excellent and competent for the tasks (select the right partners)the proposal must address all 3 criteria,convince the evaluators (don’t rely on reputation)and, of course, respect the basic rules. (deadlines, n° of participants, ceilings, length, ethics…)
94Thanks for your attention ! Health NCP for ITALYAPRE,Agenzia per la promozione della Ricerca EuropeaVia Cavour 71, Roma